Revolutionising Participant Safety Monitoring with Advanced Solutions

Adverse event (AE) monitoring and participant safety are entering a new era. Join us for a groundbreaking webinar where we unveil how cutting-edge technologies are transforming safety monitoring – enhancing detection, accelerating response times, and setting new standards for excellence. Explore the innovations driving this revolution, unlocking unprecedented opportunities to safeguard participants and optimise trial performance.

The session will conclude with a thought-provoking panel discussion where industry experts will share their perspectives on the shifting landscape of safety monitoring. Don’t miss this opportunity to be part of the change!

This webinar will be taking place virtually on 23 April at 15:00–16:00 (BST) / 10:00–11:00 (EDT) / 14:00–15:00 (CEST).

Madhumita Ghosh, Capish

Madhumita Ghosh is the Director of Software Solutions at Capish, where she drives the creation of innovative tools for clinical data exploration and adverse event management. Her work enables life sciences organisations to gain insights, strengthen oversight, mitigate risks, and streamline decisions for improving efficiency and patient safety.

With extensive experience across life sciences and technology companies, including IQVIA, Madhumita has played a key role in centralised monitoring initiatives, delivering solutions for proactive risk detection and data-driven trial monitoring. Beyond centralised monitoring, she has worked in software solutions, data analytics and process optimisation, which has given her a deep understanding of modern clinical trial complexities.

Madhumita holds a bachelor’s degree in economics and finance, a diploma in software development, and a master’s certification in project management from The George Washington University. She is an active member of the PHUSE RBQM Working Group and is passionate about fostering collaboration, building strategic partnerships and delivering impactful solutions in clinical research.

Eva Kelty, Capish

Eva Kelty is the CEO of Capish, where she leads the development of cutting-edge software solutions for data integration, exploration and visualisation in the life sciences sector. With extensive experience in clinical research consulting and software development, she is dedicated to transforming complex data into actionable insights.

Eva’s leadership focuses on empowering organisations to enhance safety monitoring, improve adverse event management and streamline clinical trial operations through innovative technologies. Her strategic vision and deep understanding of industry challenges drive the development of solutions for better decision-making and improved outcomes.

Eva holds a BSc in Systems Analysis with a focus in statistics and an MBA from Henley Management College. Her strong analytical foundation helps her navigate the evolving landscape of data-driven research.

Jenn Krohn, Gilead Sciences

Jennifer Krohn, MS, is Associate Director, RBQM at Gilead Sciences. Jenn advises study teams on implementing risk-based strategies and leads initiatives working to develop enhanced technology and processes for centralised monitoring, risk assessments and site monitoring approaches. This role expands on her 16 years’ experience in the CRO sector, where she spent a decade helping build centralised monitoring, leading data analyst teams and serving as QTL BPO. Prior to the RBQM space, Jenn worked in clinical trial roles across therapeutic areas, from site level as study coordinator to the CRO side in clinical (CRA), data management and feasibility. 

Jenn co-leads the PHUSE RBQM Working Group and previously co-led the PHUSE Central Monitoring Working Group project. Jenn holds a master’s degree in biology with a focus in biochemistry and physiology from the University of North Carolina Wilmington.